Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490767 | ||
| 003 | CHVBK | ||
| 005 | 20210128100506.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0828-1 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0828-1 | ||
| 245 | 0 | 0 | |a Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era |h [Elektronische Daten] |c [Takeshi Yuasa, Naoko Inoshita, Hajime Tanaka, Shinji Urakami, Shinya Yamamoto, Yasuhisa Fujii, Hitoshi Masuda, Iwao Fukui, Yuichi Ishikawa, Junji Yonese] |
| 520 | 3 | |a Background: The outcome of surveillance for Japanese patients with clinical stage I testicular germ cell cancer (GCC) was investigated in the multi-detector computed tomography (MDCT) era. Methods: The medical records of 92 Japanese patients with stage I GCC, who received treatment in our institution between March 1999 and February 2013, were reviewed. As six patients requested and received prophylactic chemotherapy and two patients seriously deviated from surveillance schedule, these patients were excluded from the study. Data from a total 84 patients were analyzed, Results: The median follow-up period following diagnosis was 5.1years (inter-quartile range: IQR, 2.3-7.7years). Of the 84 patients, eight (9.5%) had a recurrence of their cancer in this observation period. Regarding histologic subtypes, the recurrence rates were five (9.3%) of the 54 patients with seminoma and three (10%) of the 30 patients with nonseminomatous germ cell tumor (NSGCT). All eight patients who experienced a recurrence did so within 2years; they all underwent induction chemotherapy and remain alive at the time of writing, with no evidence of disease. Among 31 seminoma patients with a tumor more than 4cm in size and rete testis invasion, cancer recurred in three (9.7%) during the surveillance period. On the other hand, among the 13 patients with NSGCT and vascular invasion, three (23%) experienced a recurrence, whereas the figure was zero for the 11 (0%) patients without vascular invasion. Conclusion: Fewer than 10% of Japanese patients with stage I testicular GCC suffered a recurrence in the 5-year observation period of this study. The risk of occult disease, which will result in relapse, might be decreased in the MDCT era. All patients must be fully informed of the anticipated recurrence rate and the potential risks of exposure to chemotherapy agents. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Testicular cancer |2 nationallicence | |
| 690 | 7 | |a Germ cell cancer |2 nationallicence | |
| 690 | 7 | |a Stage I |2 nationallicence | |
| 690 | 7 | |a Surveillance |2 nationallicence | |
| 690 | 7 | |a Multi-detector computed tomography |2 nationallicence | |
| 690 | 7 | |a Recurrence free survival |2 nationallicence | |
| 690 | 7 | |a GCC : Germ cell cancer |2 nationallicence | |
| 690 | 7 | |a NSGCT : Nonseminomatous germ cell tumor |2 nationallicence | |
| 690 | 7 | |a MDCT : Multi-detector computed tomography |2 nationallicence | |
| 690 | 7 | |a CT : Computed tomography |2 nationallicence | |
| 690 | 7 | |a AFP : Alpha-fetoprotein |2 nationallicence | |
| 690 | 7 | |a hCG : Human chorionic gonadotropin |2 nationallicence | |
| 690 | 7 | |a LDH : Lactate dehydrogenase |2 nationallicence | |
| 690 | 7 | |a BEP : Bleomycin, etoposide, and cisplatin |2 nationallicence | |
| 700 | 1 | |a Yuasa |D Takeshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Inoshita |D Naoko |u Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Tanaka |D Hajime |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Urakami |D Shinji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yamamoto |D Shinya |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Fujii |D Yasuhisa |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Masuda |D Hitoshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Fukui |D Iwao |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ishikawa |D Yuichi |u Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yonese |D Junji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1198-1202 |x 1341-9625 |q 20:6<1198 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0828-1 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0828-1 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yuasa |D Takeshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Inoshita |D Naoko |u Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tanaka |D Hajime |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Urakami |D Shinji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yamamoto |D Shinya |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fujii |D Yasuhisa |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Masuda |D Hitoshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fukui |D Iwao |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ishikawa |D Yuichi |u Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yonese |D Junji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1198-1202 |x 1341-9625 |q 20:6<1198 |1 2015 |2 20 |o 10147 | ||